Gubra
Gubra A/S is a Danish publicly-listed biotech combining AI-driven peptide drug discovery (via its streaMLine platform) with preclinical CRO services, serving 17 of the 20 largest global pharmaceutical companies through proprietary disease models and partnered development programs in obesity and metabolic disease.
- Company typePublic
- Founded2015
- HeadquartersHørsholm, Denmark
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Gubra does
Gubra A/S is a Danish publicly-listed biotech company (Nasdaq Copenhagen, IPO March 2023 at DKK 110/share) operating a hybrid model that combines proprietary peptide drug discovery and development with a contract research organization (CRO) services business. Headquartered in Hørsholm, Denmark, with additional offices in Cambridge, Massachusetts and Allschwil, Switzerland, the company employs approximately 300 people as of early 2026 and serves pharmaceutical and biotechnology clients globally, with documented relationships with 17 of the 20 largest pharmaceutical companies worldwide.
Gubra's core technology is the streaMLine platform, an AI/ML-driven peptide drug discovery system integrating machine learning with high-throughput peptide synthesis (over 4,000 peptides per month) to compress screening-to-candidate selection timelines to 12-15 months. Complementing this are specialized preclinical capabilities including fully automated 3D light-sheet fluorescence microscopy accommodating up to 100 brains per study, AI-driven image analysis, and proprietary disease models such as the GAN DIO-MASH mouse model ranked #1 for human translatability by the LITMUS consortium. The pipeline includes the wholly-owned GUB-UCN2 urocortin-2 analog for muscle-preserving obesity treatment (CTA filed in Germany), and partnered programs including ABBV-295 (amylin analog licensed to AbbVie, Phase 1 showed 7.75-9.79% body weight loss), BI 3034701 (triple GLP-1/GIP/NPY2 agonist with Boehringer Ingelheim, Phase 2 mid-2026), AMX0318 (GLP-1R antagonist with Amylyx, IND targeted 2027), and a PTH analog (with Camurus for hypoparathyroidism).
Revenue is generated through two primary streams: CRO preclinical services sold via direct B2B engagement with pharma/biotech R&D decision-makers, and outlicensing of drug candidates for upfront payments, development and commercial milestones, and tiered royalties. The AbbVie deal for ABBV-295 — $350M upfront with up to $1.875B in milestones plus royalties — exemplifies the licensing economics. FY2025 revenue reached DKK 2,637 million (~$390M USD), with record Q4 2025 net profit of DKK 1,700M driven primarily by the AbbVie upfront. In February 2026, Gubra launched a third business unit, Gubra Ventures, to incubate new biotech companies from internal research, alongside its existing Biotech and CRO units.
Gubra firmographics
Firmographics- Name
- Gubra
- Legal name
- Gubra A/S
- Website
- https://gubra.dk
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Gubra A/S is a Danish publicly-listed biotech combining AI-driven peptide drug discovery (via its streaMLine platform) with preclinical CRO services, serving 17 of the 20 largest global pharmaceutical companies through proprietary disease models and partnered development programs in obesity and metabolic disease.
- Ownership category
- akta.pro rank
Gubra industry classification
Industry- Product category
- Preclinical Drug Discovery and Contract Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Diabetes (General) (HLAKADAA)
Keywords
Where Gubra is headquartered
LocationHeadquarters
- HQ city
- Hørsholm
- HQ country
- Denmark
- HQ region
- Europe
Offices3 records
Markets served
Gubra business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Licensing and Milestone Payments: Revenue from outlicensing drug candidates to pharmaceutical partners. Gubra receives upfront payments, development milestones, commercial milestones, and royalties on net sales. The landmark AbbVie deal for ABBV-295 included $350M upfront and up to $1.875B in milestones plus royalties.
- CRO Services (Contract Research Organization): Preclinical contract research services provided to pharmaceutical and biotech companies across multiple therapeutic areas including liver, obesity, kidney, CNS, lung, diabetes, women's health, and muscle research. Services include 3D imaging, histology, RNA sequencing, and non-rodent studies.
- Milestone Payments from Collaborations: Payments received upon achievement of development milestones. For example, $4m milestone payment from Amylyx for selection of AMX0318 as development candidate, with potential milestones exceeding $50m plus royalties.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Gubra product offering
Product offeringCore offering
Gubra is an integrated biotech company that discovers and develops peptide-based therapeutics (with a focus on obesity and metabolic diseases) and provides preclinical contract research services to pharmaceutical and biotech companies. The company operates three business units: Gubra Biotech (internal drug discovery), Gubra CRO Services (preclinical contract research), and Gubra Ventures (incubator for new biotech companies). Service offerings span in vivo pharmacology, 3D imaging, and translational research, supported by the proprietary streaMLine AI platform.
Product overview
Gubra operates as an integrated biotech company organized into three synergistic business units: Biotech, CRO Services, and Ventures. The Biotech unit advances proprietary peptide drug candidates including GUB-UCN2 for obesity (muscle-preserving weight loss) and manages partnered programs including ABBV-295 (amylin analog, licensed to AbbVie), BI 3034701 (triple agonist, Boehringer Ingelheim), AMX0318 (Amylyx), and PTH analog (Camurus). The CRO Services unit provides preclinical contract research across liver, obesity, kidney, CNS, lung, diabetes, women's health, and muscle areas, supported by specialized technologies including 3D imaging, histology, and RNASeq. The Ventures unit creates new biotech companies from Gubra's research. Core technology includes the streaMLine AI-driven peptide discovery platform and GubraView data visualization tool. The company also operates Gubra Green, a sustainability subsidiary committing 10% of pre-tax profits to environmental initiatives.
Differentiator
Problem solved
Functional benefit
Brands
- Gubra Green: Gubra's dedicated business unit for investing 10% of annual pre-tax profits in initiatives supporting greenhouse gas emissions reduction and biodiversity restoration.
Products and services
- Gubra CRO Services Preclinical contract research organization offering in vivo pharmacology, in vitro assays, 3D imaging, and translational studies to biotech and pharmaceutical clients, with deep specialization in metabolic, obesity, gastrointestinal, and CNS disease models.
- Gubra Biotech (Internal Drug Discovery & Licensing) Proprietary peptide-based drug discovery and development unit focused on obesity, metabolic disease, and related indications. Generates licensable drug candidates (e.g., GUB-UCN2, AMX0318, PTH Analog, ABBV-295, BI 3034701) for pharmaceutical partners.
- Gubra Ventures Biotech incubator and venture creation unit that builds and launches new companies based on Gubra's research capabilities and discoveries.
Quantifiable outcome
- ABBV-295 achieved 7.75% to 9.79% body weight loss in Phase 1 trial after ~3 months
- +3 more outcomes
Companies that use Gubra
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Gubra technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Gubra partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, flagship and minor.
- CamuruscoreCollaboration to develop long-acting treatment for hypoparathyroidism combining Gubra's PTH analogue with Camurus' FluidCrystal technology to enable extended, patient-friendly dosing.
- AbbVieflagshipLicense agreement for GUB014295 (ABBV-295), Gubra's long-acting amylin analog for obesity treatment. AbbVie received global rights to develop and commercialize. Gubra receives $350M upfront and up to $1.875B in development, commercial and sales milestones plus tiered royalties. Phase 1 trials showed 7.75-9.79% body weight loss.
- Amylyx PharmaceuticalscoreResearch collaboration to develop AMX0318, a novel long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. $4M milestone paid for development candidate selection; potential milestones exceeding $50M plus royalties. IND targeted for 2027.
- FerringminorCollaboration on inflammatory bowel disease (IBD) research.
- BayerminorCollaboration to develop next generation cardiorenal treatments. (Collaboration subsequently terminated per 2023 announcement)
- JDRFminorCollaboration to develop a new glucose responsive insulin for diabetes.
- SanofiminorResearch collaboration to discover and develop peptide-based drugs targeting diabetes and obesity. Gubra reached third research milestone under this agreement.
- Boehringer IngelheimcoreMultiple obesity partnerships: BI 3034701 (triple GLP-1/GIP/NPY2 agonist) advanced to Phase 2 in 2026; BI 1820237 (NPY2R agonist) discontinued for obesity but opportunities outside obesity being explored. Boehringer responsible for global clinical development and commercialization.
- HemabminorCollaboration for PTH analog development for bleeding disorder treatment.
- DTU Science ParkminorLandlord and facility provider for Gubra's expanded laboratory and office space at DTU Science Park in Hørsholm, Denmark. 70% space expansion to nearly 10,000 m².
Scale indicators11 records
Recent moves9 records
Expansion highlights6 records
Gubra competitors and assessment
Company assessmentEmerging players
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Partial overlap with Gubra's streaMLine platform thesis, though focused on small molecules and rare diseases.
- BioAge Labs: Clinical-stage metabolic disease biotech focused on obesity and related conditions. Comparable emerging-player peer overlapping Gubra's metabolic/obesity pipeline focus.
- Crown Bioscience: Preclinical CRO specializing in oncology and metabolic disease models, including MASH/NASH capabilities. Closest mid-sized CRO peer to Gubra's specialized preclinical service portfolio.
Direct peers
- Zealand Pharma: Danish peptide therapeutics company developing its own metabolic/obesity pipeline and partnering with larger pharma. Closest geographic and mechanistic peer to Gubra, with similar hybrid platform-and-pipeline orientation.
- PeptiDream: Japan-based peptide discovery platform company using proprietary technology to generate therapeutic peptides for pharma partners. Highly comparable to Gubra's streaMLine platform and outlicensing model.
- Schrödinger: AI/ML-driven drug discovery platform with co-development and licensing revenue streams. Comparable to Gubra's streaMLine platform positioning, although Schrödinger operates more broadly across small molecules and biologics.
Broad incumbents
- Novo Nordisk: Danish global leader in diabetes and obesity therapeutics (GLP-1 class originator). Not a direct competitor in discovery but the dominant force in the metabolic disease indications Gubra's pipeline targets.
- Eli Lilly: Global pharmaceutical leader with dominant position in obesity (Mounjaro/Zepbound). Operates at the commercialization end of the value chain that Gubra's partnered assets flow into.
- Charles River Laboratories: Largest preclinical CRO with broad service offerings including discovery and safety assessment. Comparable Gubra's CRO Services business unit, though at vastly greater scale.
- Labcorp: Diversified CRO with early development services comparable to Gubra's preclinical CRO offerings. Operates at much larger scale across multiple therapeutic areas.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Gubra social profiles
Digital presenceGubra financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gubra leadership team
Management profileNumber of profiles
Profiles12 records
Gubra subsidiaries and ownership
Company hierarchySubsidiaries1 record
Gubra funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gubra M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gubra
What does Gubra do?
Gubra is an integrated biotech company that discovers and develops peptide-based therapeutics (with a focus on obesity and metabolic diseases) and provides preclinical contract research services to pharmaceutical and biotech companies. The company operates three business units: Gubra Biotech (internal drug discovery), Gubra CRO Services (preclinical contract research), and Gubra Ventures (incubator for new biotech companies). Service offerings span in vivo pharmacology, 3D imaging, and translational research, supported by the proprietary streaMLine AI platform.
Is Gubra a public or private company?
Gubra is a public company. It is classified as public and is currently operating.
When was Gubra founded?
Gubra was founded in 2015. It employs 251 to 500 people.
Where is Gubra based?
Gubra is headquartered in Hørsholm, Denmark, in the Europe region.
How does Gubra make money?
Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are CRO Services (Contract Research Organization) and milestone Payments from Collaborations.
Who are Gubra's main competitors?
Emerging players on record are Recursion Pharmaceuticals, BioAge Labs and Crown Bioscience. Direct peers are Zealand Pharma, PeptiDream and Schrödinger. Broad incumbents are Novo Nordisk, Eli Lilly, Charles River Laboratories and Labcorp.
Does Gubra have an API?
No public API is recorded for Gubra.
What industry is Gubra in?
Gubra's product category is Preclinical Drug Discovery and Contract Research Services. Its primary akta.pro industry code is HLAKADAA, Diabetes (General). Its NAICS code is 541714 and its SIC code is 2834.